21.04.2016
- Non-profit group the Drugs for Neglected Diseases initiative (DNDi) and Egyptian drug maker Pharco Pharmaceuticals have teamed up to launch a low-cost hepatitis C combination...
07.04.2016
- US drug maker Gilead Sciences is to pay $400 million to Nimbus Therapeutics for its subsidiary Nimbus Apollo and its Acetyl-CoA Carboxylase (ACC) inhibitor program. The ACC program...
24.03.2016
- A federal jury in California has ruled in favour of US drug maker Merck in a high-profile patent dispute with rival Gilead Sciences over sofosbuvir, the active ingredient in a new...
11.11.2015
- The US Food and Drug Administration (FDA) has approved Gilead Sciences’ Genvoya to treat HIV-1 infection. Genvoya combines four treatments – elvitegravir, cobicistat, emtricitabine...
07.10.2015
- The pharmaceutical industry is entering a period of sustained growth. Prescription drug sales are set to advance at almost 5% a year until 2020, while worldwide prescription drug...
17.07.2015
- US biotech firm Celgene has agreed to pay $7.2 billion, or $232 per share, to acquire compatriot Receptos, a biotech company that makes a potential blockbuster drug to treat...
20.01.2015
- Europe, where about 15 million people are believed to be infected with hepatitis C, could become the next battleground between US drugmakers Gilead Sciences and AbbVie in their...
19.01.2015
- The largest US health insurer, Aetna, has negotiated a discount for Gilead Sciences' hepatitis C treatment regime and said it plans to offer this as a preferred choice for its...
